Public-facing research trails for psilocybin and DMT.

Experientia report that helped establish DMT as a human psychoactive research compound.

A short historical paper often cited in the first wave of human DMT literature.

Arch Gen Psychiatry paper from the modern reopening of controlled human DMT research.

Arch Gen Psychiatry report detailing the subjective response profile and rating scale findings.

ACS Chemical Neuroscience study reporting faster cued fear extinction, better retention, reduced immobility in forced-swim tests, and an antidepressant-like phenotype in rats, while also noting a sex-specific reduction in PFC dendritic spine density in female rats that was not seen in males.

A modern lab-based human neurophysiology paper that helped renew mechanistic DMT research.

Journal of Psychopharmacology field study with 35 experienced participants.

Neuropsychopharmacology phase 1 study with 3 healthy controls and 7 participants with major depressive disorder.

Clinical pharmacology work linking plasma exposure to electrophysiologic changes.

Randomized placebo-controlled Frontiers in Psychiatry trial that informed later depression dosing.

Scientific Reports analysis spanning placebo-controlled and prospective datasets totaling 30 healthy volunteers.

This rodent study tied within-session fear-extinction effects to infralimbic cortex 5-HT2A and 5-HT1A receptor signaling.

Dose-escalation healthy-volunteer research expanding the clinical picture around combined administration.

Neuropsychopharmacology placebo-controlled crossover study with 22 participants.

The study linked reduced fear generalization and extinction benefits to infralimbic cortex BDNF-TrkB signaling in a preclinical rodent model.

Nature Medicine paper with 34 randomized participants showing rapid antidepressant effects with psychotherapeutic support.